Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications.

Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J, Cheng G, Lopez M, Kalyanaraman B.

Chem Rev. 2017 Aug 9;117(15):10043-10120. doi: 10.1021/acs.chemrev.7b00042. Epub 2017 Jun 27. Review.

PMID:
28654243
2.

Mitochondrial dysfunction activates the AMPK signaling and autophagy to promote cell survival.

Zhao B, Qiang L, Joseph J, Kalyanaraman B, Viollet B, He YY.

Genes Dis. 2016 Mar;3(1):82-87. doi: 10.1016/j.gendis.2015.12.002. Epub 2016 Jan 4.

3.

Mitoapocynin Treatment Protects Against Neuroinflammation and Dopaminergic Neurodegeneration in a Preclinical Animal Model of Parkinson's Disease.

Ghosh A, Langley MR, Harischandra DS, Neal ML, Jin H, Anantharam V, Joseph J, Brenza T, Narasimhan B, Kanthasamy A, Kalyanaraman B, Kanthasamy AG.

J Neuroimmune Pharmacol. 2016 Jun;11(2):259-78. doi: 10.1007/s11481-016-9650-4. Epub 2016 Feb 2.

4.

Antiproliferative effects of mitochondria-targeted cationic antioxidants and analogs: Role of mitochondrial bioenergetics and energy-sensing mechanism.

Cheng G, Zielonka J, McAllister D, Hardy M, Ouari O, Joseph J, Dwinell MB, Kalyanaraman B.

Cancer Lett. 2015 Aug 28;365(1):96-106. doi: 10.1016/j.canlet.2015.05.016. Epub 2015 May 21.

5.

A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease.

Dranka BP, Gifford A, McAllister D, Zielonka J, Joseph J, O'Hara CL, Stucky CL, Kanthasamy AG, Kalyanaraman B.

Neurosci Lett. 2014 Nov 7;583:159-64. doi: 10.1016/j.neulet.2014.09.042. Epub 2014 Sep 26.

6.

Real-time measurements of amino acid and protein hydroperoxides using coumarin boronic acid.

Michalski R, Zielonka J, Gapys E, Marcinek A, Joseph J, Kalyanaraman B.

J Biol Chem. 2014 Aug 8;289(32):22536-53. doi: 10.1074/jbc.M114.553727. Epub 2014 Jun 13.

7.

High-throughput assays for superoxide and hydrogen peroxide: design of a screening workflow to identify inhibitors of NADPH oxidases.

Zielonka J, Cheng G, Zielonka M, Ganesh T, Sun A, Joseph J, Michalski R, O'Brien WJ, Lambeth JD, Kalyanaraman B.

J Biol Chem. 2014 Jun 6;289(23):16176-89. doi: 10.1074/jbc.M114.548693. Epub 2014 Apr 24.

8.

Oxidative stress induced mitochondrial protein kinase A mediates cytochrome c oxidase dysfunction.

Srinivasan S, Spear J, Chandran K, Joseph J, Kalyanaraman B, Avadhani NG.

PLoS One. 2013 Oct 10;8(10):e77129. doi: 10.1371/journal.pone.0077129. eCollection 2013.

9.

Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model.

Dickey JS, Gonzalez Y, Aryal B, Mog S, Nakamura AJ, Redon CE, Baxa U, Rosen E, Cheng G, Zielonka J, Parekh P, Mason KP, Joseph J, Kalyanaraman B, Bonner W, Herman E, Shacter E, Rao VA.

PLoS One. 2013 Aug 5;8(8):e70575. doi: 10.1371/journal.pone.0070575. Print 2013.

10.

Mitochondria-targeted antioxidant and glycolysis inhibition: synergistic therapy in hepatocellular carcinoma.

Dilip A, Cheng G, Joseph J, Kunnimalaiyaan S, Kalyanaraman B, Kunnimalaiyaan M, Gamblin TC.

Anticancer Drugs. 2013 Oct;24(9):881-8. doi: 10.1097/CAD.0b013e32836442c6.

11.

Real-time monitoring of reactive oxygen and nitrogen species in a multiwell plate using the diagnostic marker products of specific probes.

Zielonka J, Joseph J, Sikora A, Kalyanaraman B.

Methods Enzymol. 2013;526:145-57. doi: 10.1016/B978-0-12-405883-5.00009-0.

PMID:
23791099
12.

Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death.

Cheng G, Zielonka J, McAllister DM, Mackinnon AC Jr, Joseph J, Dwinell MB, Kalyanaraman B.

BMC Cancer. 2013 Jun 13;13:285. doi: 10.1186/1471-2407-13-285.

13.

Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse.

Dranka BP, Gifford A, Ghosh A, Zielonka J, Joseph J, Kanthasamy AG, Kalyanaraman B.

Neurosci Lett. 2013 Aug 9;549:57-62. doi: 10.1016/j.neulet.2013.05.034. Epub 2013 May 28.

14.

Reaction between peroxynitrite and triphenylphosphonium-substituted arylboronic acid isomers: identification of diagnostic marker products and biological implications.

Sikora A, Zielonka J, Adamus J, Debski D, Dybala-Defratyka A, Michalowski B, Joseph J, Hartley RC, Murphy MP, Kalyanaraman B.

Chem Res Toxicol. 2013 Jun 17;26(6):856-67. doi: 10.1021/tx300499c. Epub 2013 May 9.

15.

Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.

Ghosh A, Kanthasamy A, Joseph J, Anantharam V, Srivastava P, Dranka BP, Kalyanaraman B, Kanthasamy AG.

J Neuroinflammation. 2012 Oct 23;9:241. doi: 10.1186/1742-2094-9-241.

16.

Hydropropidine: a novel, cell-impermeant fluorogenic probe for detecting extracellular superoxide.

Michalski R, Zielonka J, Hardy M, Joseph J, Kalyanaraman B.

Free Radic Biol Med. 2013 Jan;54:135-47. doi: 10.1016/j.freeradbiomed.2012.09.018. Epub 2012 Oct 7.

17.

Mitochondrial-targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cells.

Cunniff B, Benson K, Stumpff J, Newick K, Held P, Taatjes D, Joseph J, Kalyanaraman B, Heintz NH.

J Cell Physiol. 2013 Apr;228(4):835-45. doi: 10.1002/jcp.24232.

18.

Boronate probes as diagnostic tools for real time monitoring of peroxynitrite and hydroperoxides.

Zielonka J, Sikora A, Hardy M, Joseph J, Dranka BP, Kalyanaraman B.

Chem Res Toxicol. 2012 Sep 17;25(9):1793-9. doi: 10.1021/tx300164j. Epub 2012 Jun 25.

19.

Mitochondrial reactive oxygen species generation triggers inflammatory response and tissue injury associated with hepatic ischemia-reperfusion: therapeutic potential of mitochondrially targeted antioxidants.

Mukhopadhyay P, Horváth B, Zsengellėr Z, Bátkai S, Cao Z, Kechrid M, Holovac E, Erdėlyi K, Tanchian G, Liaudet L, Stillman IE, Joseph J, Kalyanaraman B, Pacher P.

Free Radic Biol Med. 2012 Sep 1;53(5):1123-38. doi: 10.1016/j.freeradbiomed.2012.05.036. Epub 2012 Jun 6.

20.

Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death.

Cheng G, Zielonka J, Dranka BP, McAllister D, Mackinnon AC Jr, Joseph J, Kalyanaraman B.

Cancer Res. 2012 May 15;72(10):2634-44. doi: 10.1158/0008-5472.CAN-11-3928. Epub 2012 Mar 19.

Supplemental Content

Loading ...
Support Center